Asston Pharmaceuticals IPO
Asston Pharmaceuticals is SME BSE IPO listed on the SME BSE platform, priced at ₹115–₹123 per share. The stock debuted at ₹119. The IPO had a lot size of ₹1000 shares and a minimum investment of ₹1,23,000.
Asston Pharmaceuticals Limited IPO
- IPO Dates
- Jul 9, 2025 – Jul 11, 2025
- Price band
- ₹115-123 per equity share
- Minimum Investment
- ₹1,23,000
- Issue size
- ₹27.56 Cr
- Lot size
- 1000
- Allotment Date
- Jul 14, 2025
- Listing
- Jul 16, 2025
- Listing At
- SME BSE
IPO timeline
-
Jul 9, 2025
Open Date
Completed
-
Jul 11, 2025
Close Date
Completed
-
Jul 14, 2025
Allotment Date
Completed
-
Jul 16, 2025
Listing Date
Completed
Asston Pharmaceuticals IPO Essentials
Asston Pharmaceuticals IPO Details
Asston Pharmaceuticals IPO is priced at ₹115-123 per share with a total issue size of 27.56 crore. The IPO has a lot size of 1000 shares and is listed on SME BSE.
- Issue price
- ₹115-123 per equity share
- Lot size
- 1000 shares
- Face value
- ₹10 Per Equity Share
- Issue size
- 22,41,000 shares(aggregating up to ₹27.56 Cr)
- Total issue size
- 22,41,000 shares
(aggregating up to ₹27.56 crore) - Fresh issue
- 22,41,000 shares
(aggregating up to ₹27.56 crore) - Listing at
- SME BSE
- List price
- 119.0
- Listing date
- Registrar
- Maashitla Securities Private Limited
- Lead manager
-
Sobhagya Capital Options Ltd
Market Lot Size
Investors can bid for a minimum of 2000 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 2 | 2000 | ₹2,46,000 |
| Retail(max) | 2 | 2000 | ₹2,46,000 |
| NII (min) | 3 | 3,000 | ₹3,69,000 |
Asston Pharmaceuticals IPO Reservation
Asston Pharmaceuticals IPO reservation details show category-wise allocation of shares. Out of the total 32,64,000 shares, approximately 18.97% are reserved for QIB, 14.26% for NII, 33.28% for retail investors, 5.05% for market maker, and 28.43% for anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | NA (28.43%) | |
| Market Maker Shares Offered | NA (5.05%) | |
| QIB Shares Offered | NA (18.97%) | |
| NII (HNI) Shares Offered | 4,65,600 (14.26%) | |
| Retail Shares Offered | 10,86,400 (33.28%) | |
| Total Shares Offered | 32,64,000 (100%) |
Asston Pharmaceuticals IPO Analytics
Asston Pharmaceuticals IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Asston Pharmaceuticals IPO Subscription Status
Asston Pharmaceuticals IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO subscription status indicates investor demand across categories.
| As on | QIB |
NII
bHNI
sHNI
|
Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 4,25,000 |
3,22,000
2,15,000
1,07,000
|
7,46,000 | 14,93,000 |
|
Day 1
09-07-25 06:00 PM
|
3.51 x |
0.66x
0.00x
0.00x
|
1.22 x | 1.75 x |
|
Day 2
10-07-25 06:00 PM
|
4.47 x |
19.67x
19.29x
21.50x
|
16.66 x | 13.84 x |
|
Day 3
11-07-25 06:00 PM
|
85.76 x |
353.14x
424.47x
210.85x
|
210.85 x | 186.55 x |
Asston Pharmaceuticals Valuations
Earnings
- EPS Pre IPO
- ₹6.90/-
- EPS Post IPO
- ₹9.32/-
- P/E Pre IPO
- 17.83
- P/E Post IPO
- 13.20
Returns
- ROE
- 50.56%
- ROCE
- 51.25%
- RoNW
- 40.36%
- PAT Margin
- 17.27%
Fundamentals
- Debt / Equity
- 0.68
- Price / Book
- 12.07
Asston Pharmaceuticals Financials( In Crs.)
| 31-Mar-25 | 31-Mar-24 | 31-Mar-23 | |
|---|---|---|---|
| Assets | 28.12 | 20.26 | 13.69 |
| Revenue | 25.61 | 15.84 | 7.19 |
| Profit After Tax | 4.33 | 1.36 | 1.06 |
| Net Worth | 10.72 | 6.39 | 1.99 |
| Reserves & Surplus | 4.45 | 5.61 | 1.29 |
| Total Borrowing | 7.26 | 6.82 | 5.25 |
Asston Pharmaceuticals Company & Offer Insights
About Asston Pharmaceuticals
Established in 2019, Asston Pharmaceuticals Limited is a pharmaceutical business dealing with the export of healthcare products worldwide.
The firm deals with a wide array of products like tablets, capsules, sachets, and syrups. Its product line covers different therapeutic classes like analgesics, antibiotics, antifungals, vitamins, etc.
The company makes direct sales medicines and also on a contract manufacturing or loan license, majorly operating on a principle-to-principle basis with different marketers.The company is certified by both State and Central FDA, NQA (Nuclear Quality Assurance) accredited, and adheres to Quality Management System (QMS) guidelines in terms of high-quality production.
Products:
Albendazole USP 400 mg: Albendazole USP 400 mg is a higher strength of Albendazole, a broad-spectrum anthelmintic (anti-worm) medication which is used for the treatment of different parasitic worm infections.
Diclofenac 100 mg: Diclofenac 100 mg is a particular strength of Diclofenac, a widely used nonsteroidal anti-inflammatory drug (NSAID).
Ibuprofen, paracetamol: Ibuprofen and Paracetamol (Acetaminophen) are two frequently used over-the-counter medications, typically used to relieve pain and decrease fever.
Ferrovit Syrup: For the management of vitamin and mineral deficiencies.
As of 3 July 2025, there are 46 Permanent staff and 6 contractual staff in the different departments.
Asston Pharmaceuticals Promoter(s)
Dr. Ashish Narayan Sakalkar, Saili Jayaram More, Sachin Chandrakant Badakh are the company's promoters of Asston Pharmaceuticals.
Asston Pharmaceuticals IPO Issue Objectives
- •
- Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit
- •
- Funding the incremental working capital requirements of the Company
- •
- Repayment and/or prepayment, in part or full, of certain of the outstanding borrowings availed by the Company
- •
- General Corporate Purposes
Contact Information
Contact Details
Asston Pharmaceuticals
+91 22 49731411
info@asstonpharmaceuticals.com
http://www.asstonpharmaceuticals.com/
4th Floor, Office No. A-431 Balaji Bhavan, Plot No 42A Sector-11 CBD Belapur, Navi Mumbai, Thane, Navi Mumbai, Maharashtra, 400614
Registrar Contact Details
Maashitla Securities Private Limited
+91-11-45121795-96
Frequently Asked Questions
Click any question to reveal the answer
Asston Pharmaceuticals IPO is a book-built IPO worth ₹27.56 crore. The price band is ₹115–₹123 per share. The IPO opens on Jul 9, 2025 and closes on Jul 11, 2025. It will be listed on SME BSE SME Platform. Maashitla Securities Private Limited is the registrar.
The price band of Asston Pharmaceuticals IPO is ₹115 to ₹123 per share.
The lot size of Asston Pharmaceuticals IPO is 1000 shares.
The minimum investment for Asston Pharmaceuticals IPO is approximately ₹1,23,000 based on the upper price band .
Asston Pharmaceuticals IPO opens on Jul 9, 2025 and closes on Jul 11, 2025.
The allotment date of Asston Pharmaceuticals IPO is Jul 14, 2025.
Asston Pharmaceuticals IPO is expected to be listed on Jul 16, 2025, on SME BSE SME Platform.
Asston Pharmaceuticals IPO valuation snapshot: P/E 13.20, EPS ₹9.32/-, P/B 12.07, RoNW 40.36%, and market cap N/A.
To apply for Asston Pharmaceuticals IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Asston Pharmaceuticals IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Asston Pharmaceuticals IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Asston Pharmaceuticals IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Asston Pharmaceuticals IPO allotment status on IPO Ji for quick and easy access.